Soft Tissue Sarcoma Surgery — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Soft tissue sarcomas (STS) are rare malignant tumours arising from connective tissues including fat (liposarcoma), smooth muscle (leiomyosarcoma), fibrous tissue (fibrosarcoma), synovium (synovial sarcoma), and blood vessels (angiosarcoma). Together they account for approximately 1% of adult cancers. Surgical wide local excision — removing the tumour with a margin of healthy tissue — is the cornerstone of curative treatment. The goal is R0 resection (clear microscopic margins) while preserving functional limb anatomy whenever possible. Limb-sparing surgery is now achievable in over 90% of extremity sarcomas, replacing the historical practice of amputation.

STS are classified by histological subtype (over 50 recognised subtypes) and grade. Low-grade sarcomas (FNCLCC grade 1) have less than 5% metastatic risk; high-grade sarcomas (grade 3) carry 30–50% metastatic risk. The most common STS subtypes include undifferentiated pleomorphic sarcoma (UPS, previously MFH), liposarcoma (most common — subdivided into well-differentiated, myxoid, pleomorphic subtypes), leiomyosarcoma, synovial sarcoma, and GIST (gastrointestinal stromal tumour). Specialist referral to a designated sarcoma centre is mandatory before biopsy, as improper biopsy technique can contaminate tissue planes and compromise subsequent limb-sparing surgery. Referral to a designated sarcoma MDT (multidisciplinary team) is mandatory for all suspected soft tissue sarcomas before biopsy.

Surgery is indicated for localised and selected locally advanced soft tissue sarcomas in patients fit for general anaesthesia. Any new soft tissue mass exceeding 5 cm, a deep mass at any size, or a mass growing in size should be referred urgently to a sarcoma specialist multidisciplinary team (MDT) before biopsy or excision is attempted elsewhere. Neoadjuvant (pre-operative) chemotherapy or radiotherapy is used for large high-grade tumours (>5 cm, Grade 2–3) to reduce tumour burden before surgery. Patients with oligometastatic pulmonary disease may also benefit from surgical resection with curative intent in carefully selected cases.

Any deep or rapidly growing soft tissue mass, or any mass greater than 5 cm, mandates urgent core needle biopsy under ultrasound or CT guidance at a sarcoma centre before any excision is attempted. 'Whoops procedures' — unplanned excisions of sarcoma without adequate margins at non-specialist centres — occur in 30–40% of cases and require wider re-excision (associated with worse local control) or amputation. Staging CT of chest (lungs — primary metastatic site) and abdomen is performed for all STS. MRI of the primary site provides superior soft tissue contrast for defining surgical margins.

Under general anaesthesia, the surgeon excises the tumour en bloc with a surrounding cuff of normal tissue (1–2 cm for high-grade STS) guided by preoperative MRI mapping. The fascial plane around the tumour is preserved as the surgical margin where possible. Intraoperative frozen sections confirm margin status in selected cases. Reconstruction following excision uses primary closure for small defects, local fascio-cutaneous or muscle flaps for medium defects (e.g., rectus abdominis, latissimus dorsi), and free tissue transfer microvascular flaps for large complex defects. Vascular reconstruction with synthetic graft or autologous vein is occasionally required for tumours involving major vessels.

Neoadjuvant radiotherapy (50 Gy in 25 fractions) is administered before surgery for most high-grade limb or limb-girdle sarcomas at specialist centres, shrinking the tumour, improving margin rates, and potentially reducing the required surgical volume. Intraoperative frozen section analysis of margin biopsies guides real-time extension of excision. Retroperitoneal sarcomas (liposarcoma, leiomyosarcoma) require en bloc resection of adjacent organs (kidney, bowel, spleen) to achieve adequate margins in most cases.

Pre-operative MRI of the primary site with gadolinium contrast is the gold-standard imaging modality, defining tumour extent, compartmental involvement, relationship to neurovascular structures, and viable versus necrotic tumour for biopsy targeting. Core needle biopsy under image guidance provides tissue for histological subtyping and grading without contaminating the surgical field if performed through the planned incision line.

Wide local excision with clear margins achieves local control in 80–90% of extremity STS cases, with 5-year overall survival of 60–75% for high-grade localised disease. Low-grade STS has better prognosis with 5-year survival approaching 90%. Limb-sparing surgery combined with radiotherapy provides equivalent local control and survival to amputation while preserving function and quality of life. Neoadjuvant radiotherapy reduces local recurrence rates to below 10% for extremity STS at 10 years. Surgical expertise at a dedicated sarcoma centre is the single most important factor in achieving R0 resection and improving outcome.

Limb-sparing surgery (wide local excision) achieves equivalent local control and survival to amputation in appropriately selected extremity STS — established by the landmark NCI trial (Rosenberg et al.) — provided clear histological margins are achieved and radiotherapy is used. Functional outcomes after limb-sparing surgery are superior to amputation in most domains at 5-year follow-up. Imatinib (Gleevec) has transformed GIST management: achieving durable disease control in over 80% of advanced GIST and enabling neoadjuvant tumour shrinkage that allows R0 resection of previously unresectable primary tumours.

Wound complications occur in 20–35% of cases, particularly after neoadjuvant radiotherapy (which impairs tissue healing). Wound dehiscence, seroma, haematoma, and deep wound infection may require further surgery or vacuum-assisted closure. Neurovascular injury can cause sensory or motor deficits depending on tumour location. Local recurrence occurs in 10–20% of cases even with R0 margins in high-grade tumours and is managed with re-excision, further radiotherapy, or ablative techniques. Amputation is required in fewer than 10% of extremity STS patients at sarcoma specialist centres.

Local recurrence occurs in 10–20% of R0-resected high-grade STS despite combined modality treatment, usually within the first 2–3 years, requiring re-resection and further radiotherapy if feasible. Distant metastases (predominantly to lungs) develop in 30–50% of high-grade STS patients. Pulmonary metastatectomy (surgical resection of lung metastases) is beneficial for selected patients with resectable oligometastatic lung disease, achieving 5-year survival of 20–35%. Long-term radiotherapy consequences include fibrosis, joint stiffness, and secondary malignancy risk within the radiation field.

Hospital stay is 3–7 days for straightforward excisions; longer after complex reconstruction. Closed-suction drains are removed when output falls below 30 mL per day. Physiotherapy begins early to restore mobility and prevent contracture, particularly after lower extremity surgery. Adjuvant radiotherapy (if not given pre-operatively) begins 4–6 weeks post-surgery when the wound has healed. Surveillance with MRI of the operative site every 3–6 months for the first 2 years, then annually, detects early local recurrence. Chest CT every 3–6 months monitors for pulmonary metastases, the most common site of distant spread in STS.

Physiotherapy, occupational therapy, and prosthetics/orthotics are central to functional rehabilitation after sarcoma surgery, particularly for lower limb resections affecting weight-bearing joints or resections requiring prosthetic skeletal reconstruction. Oncological surveillance with MRI of the primary site every 3–4 months for 2 years, then 6-monthly for 3 more years, and CT chest every 3–4 months for the first 3 years detects local recurrence and pulmonary metastases at a surgically treatable stage. Histology-specific systemic treatments (chemotherapy with doxorubicin and ifosfamide, targeted agents for specific subtypes) are considered for metastatic disease.